• argenx’s Phase 3 ALKIVIA trial met primary and key secondary endpoints for efgartigimod in combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis populations.
• IMNM patients showed statistically significant, clinically meaningful improvement; the disease has no approved treatments.
• Dermatomyositis patients experienced clinically meaningful benefits, but results did not reach statistical significance in the smaller cohort.
• An FDA supplemental biologics license application for IMNM is planned by year-end 2026, supported by Breakthrough Therapy Designation.
• Results will be presented at American College of Rheumatology Convergence on November 11, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. arGEN-X SE published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-124180), on November 09, 2026, and is solely responsible for the information contained therein.